Company news
XBiotech Inc. news in 2021
XBiotech Inc.'s news releases, calls and decks from 2021, newest first.
FDA Approves XBiotech’s IND in Rheumatology
December 12, 2021
XBiotech to Launch Novel Candidate Therapy for Stroke
October 27, 2021
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
September 7, 2021
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
August 29, 2021
XBiotech Announces Payment of Dividend to Holders of Common Stock
July 29, 2021
XBiotech Announces Dividend to Holders of Common Stock
July 5, 2021
XBiotech Announces Receipt of $75 Million from Sale of Antibody
June 29, 2021
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
June 22, 2021
French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
May 2, 2021
FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
April 18, 2021
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
January 20, 2021
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
January 18, 2021